Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • NX-13

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    Lilly’s Omvoh shows improved outcomes in ulcerative colitis

    The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures

    - PMLiVE

    Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

    The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

    - PMLiVE

    AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

    Follicular lymphoma affects around 15,000 people in the US every year

    - PMLiVE

    AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

    Around 700,000 people in the US are living with some form of the autoimmune disease

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

    Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

    - PMLiVE

    Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

    The companies will focus on inflammatory diseases that have been historically difficult to treat

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    - PMLiVE

    AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

    The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

    - PMLiVE

    Eli Lilly’s Omvoh recommended by NICE to treat Crohn’s disease in adults

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    - PMLiVE

    J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links